Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22752
Title: Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts.
Authors: Yang, J C-H;Ramalingam, S S;Lee, C K;Kurata, T;Kim, D-W;John, Thomas;Nogami, N;Ohe, Y;Rukazenkov, Y;Murphy, M;Jänne, P A
Affiliation: National Taiwan University and National Taiwan University Cancer Center, Taipei City, Taiwan
Austin Health, Heidelberg, Victoria, Australia
St. George Hospital, Sydney, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Emory School of Medicine, Winship Cancer Institute, Atlanta, GA, USA
Kansai Medical University Hospital, Osaka, Japan
Seoul National University Hospital, Seoul, Republic of Korea
National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
AstraZeneca, Cambridge, UK
Dana-Farber Cancer Institute, Boston, MA, USA
Issue Date: Apr-2019
Citation: Annals of oncology : official journal of the European Society for Medical Oncology 2019; 30 Suppl 2: ii48
URI: http://ahro.austin.org.au/austinjspui/handle/1/22752
DOI: 10.1093/annonc/mdz063.020
PubMed URL: 32131238
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.